AngolaTuberculosis profile
Population  2014 24 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 13 (7.5–19) 52 (31–79)
Mortality (HIV+TB only) 3.5 (1.5–6.2) 14 (6.2–26)
Prevalence  (includes HIV+TB) 120 (61–200) 490 (251–807)
Incidence  (includes HIV+TB) 90 (58–130) 370 (240–529)
Incidence (HIV+TB only) 23 (14–34) 95 (58–141)
         
Case detection, all forms (%) 60 (42–92)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
800 (140–1 500) 740 (190–1 300)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 22 046   2 682
Pulmonary, clinically diagnosed 25 262   0
Extrapulmonary 3 562   0
       
Total new and relapse 53 552    
Previously treated, excluding relapses 1 654    
Total cases notified 55 206    
Among 22 046 new and relapse cases:
909 (4%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 29 (<1%) 214 (5%) 243
Laboratory-confirmed RR-/MDR-TB cases     307
Patients started on MDR-TB treatment ***     307
TB/HIV 2014 Number (%)
TB patients with known HIV status 27 699 (50)
HIV-positive TB patients 2 827 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 2 827 (100)
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (23) 60 807
Previously treated cases, excluding relapse, registered in 2013 (39) 6 844
HIV-positive TB cases, all types, registered in 2013   24 445
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.4
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 24
% Funded domestically 30%
% Funded internationally 13%
% Unfunded 57%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-28 Data: www.who.int/tb/data